Moderna - AI Stock Analysis

Analysis generated December 7, 2025

Moderna, Inc. is a biotechnology company focused on drug discovery, drug development, and vaccine technologies based on messenger RNA (mRNA). Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna gained significant recognition and growth potential through its development of the mRNA-based COVID-19 vaccine. The company’s innovation in mRNA technology positions it at a pivotal standpoint for not just the present but also future healthcare solutions.

Fundamental Analysis

In the last quarter, Moderna reported a revenue of $1.02 billion. This represents a substantial increase of 615.49% compared to the previous quarter, indicating a strong rebound. However, it's important to note that this is a 45.23% decrease compared to the same quarter last year, which may affect investor sentiment.

The company’s net income for the last quarter was $200 million, showcasing an increase of 75.76% compared to the previous quarter. This positive growth is tempered by the fact that there is a sharp decline of 1,638.46% compared to the same quarter last year, a striking figure that suggests challenges in maintaining profit levels quarter-over-quarter.

Moderna’s EBITDA for the last quarter stood at $260 million, marking an increase of 65.79% from the quarter prior. However, a 429.11% decrease compared to the same quarter last year highlights volatility in operational efficiency. These numbers combined illustrate a mixed picture of strong recent growth but significant longer-term challenges.

Technical Analysis

Today’s stock price for Moderna is $27.70, reflecting an increase of 12.88% from a month ago, suggesting a positive short-term trend. Nevertheless, there is a longer-term decrease of 37.67% compared to the stock's price a year ago, which might concern some investors.

The stock’s trend is currently bullish. The 10-day Simple Moving Average (SMA10) is $25.99, higher than the previous SMA10 of $25.72, signaling a potential upward trend. Additionally, the Relative Strength Index (RSI) is at 29.9, indicating a potentially oversold condition and suggesting a bullish setup.

Alternative Data Analysis

Moderna has 125 job openings, down by 23% over the past couple of months. This reduction could signify attempts to improve margins or cost-cutting measures, not typically indicative of expansion in growth-oriented companies.

Only 29% of employees at Moderna have a positive business outlook, a concerning figure which might reflect internal challenges or diminishing morale within the company.

Customer acquisition data shows a bullish trend with 580,000 visitors to Moderna’s webpage, a notable increase of 278% recently. However, customer engagement appears stagnant with 140,000 followers on their Twitter page, unchanged over the past couple of months.

AltIndex’s AI score, which predicts stock price trends based on a combination of fundamental, technical, and alternative data, rates Moderna at 25. This low score indicates a strong sell signal, highlighting investor apprehension about the stock’s prospects.

Conclusion and Recommendation

Moderna’s stock demonstrates a mixed outlook. The company shows strong recent growth, evident through an impressive recovery in its quarterly revenue and net income, but faces significant challenges compared to figures from the previous year. Technical indicators present a short-term bullish scenario, but longer-term trends and alternative data analysis raise some concerns.

Given the detailed data, a cautious approach is recommended. While the technical analysis allows for potential short-term gains, fundamental and alternative data suggest uncertainties in the longer run. Investors should weigh these factors carefully and possibly look for further stabilization before making a substantive commitment to Moderna’s stock.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.